Recurrence of Cardiac Sarcoidosis 7 Years Post Heart Transplant

Hsiao, Stephanie; Tsai, Shirley C.; Pham, Michael; Herr, Jared

doi:10.1016/s0735-1097(19)33304-2

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, concerns of sarcoid recurrence, which is both rare and usually experienced without mortality, and of right heart dysfunction due to pulmonary disease, have been mitigated by recent literature. 12,17,22 In light of our study's findings and other recent data, cardiac sarcoidosis should be considered a viable indication for transplant in selected patients with the expectation of excellent long-term survival and morbidity.…”

Section: Causes Of Deathsupporting

confidence: 60%

Long‐term survival after heart transplantation for cardiac sarcoidosis

McGoldrick

Giuliano

Etchill

et al. 2021

Journal of Cardiac Surgery

View full text Add to dashboard Cite

Background Cardiac sarcoidosis is an increasingly common indication for a heart transplant, but there is a paucity of knowledge with regard to long‐term outcomes following transplant. Methods We utilized the Organ Procurement and Transplantation Network database to retrospectively analyze adult patients undergoing first‐time, single‐organ heart transplant between January 1999 and March 2020. Results Of the 41,447 patients that underwent heart transplant during the study period, 289 (0.7%) were transplanted for a primary diagnosis of restrictive cardiomyopathy due to cardiac sarcoidosis (RCM‐Sarcoidosis). RCM‐Sarcoidosis was associated with 33% reduced risk of mortality over 10 years compared to non‐RCM indications in a multivariable Cox proportional hazards model (p = .03). Ten‐year survival functions were improved among RCM‐Sarcoidosis compared to this reference group (73.4% [64.2%–80.6%] vs. 59.5% [58.8%–60.1%], p = .002). Among patients transplanted after 1999 who had at least 10 years of follow‐up (n = 19,489), median survival of RCM‐Sarcoidosis patients was 11.9 [8.3–14.6] years while that of non‐RCM patients was 9.9 [4.0–13.1] years. RCM‐Sarcoidosis was not associated with an increased risk of secondary outcomes such as graft failure, rejection, or infection. The incidence of retransplant was comparable between RCM‐Sarcoidosis and non‐RCM patients (1.38% vs. 1.50%, p = .93). Conclusions These data suggest that long‐term outcomes following transplant for cardiac sarcoidosis are favorable compared to heart transplant for other indications.

show abstract

Section: Causes Of Deathsupporting

confidence: 60%